P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

Eur J Haematol. 2010 Apr;84(4):359-61. doi: 10.1111/j.1600-0609.2009.01399.x. Epub 2009 Dec 14.

Abstract

We report a patient with multiple myeloma presenting with a paraspinal plasmacytoma with a marked dissociation between the response obtained in bone marrow (BM) infiltration and that achieved in soft tissue masses. While a complete remission was reached and maintained in BM, extramedullary plasmacytomas were refractory to every line of treatment. Genetic analysis identified the presence of t(4;14) and RB deletion in myeloma cells of both origins. However, a P53 deletion was only detected in plasma cells from extramedullary plasmacytomas. This finding suggests that P53 deletion has a role in the lack of treatment response of extramedullary plasmacytomas.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosomes, Human, Pair 14 / genetics
  • Chromosomes, Human, Pair 4 / genetics
  • Female
  • Gene Deletion*
  • Humans
  • Middle Aged
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / therapy
  • Neoplasms, Second Primary / genetics*
  • Neoplasms, Second Primary / therapy
  • Plasmacytoma / genetics*
  • Plasmacytoma / therapy
  • Retinoblastoma Protein / genetics
  • Translocation, Genetic / genetics
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Retinoblastoma Protein
  • TP53 protein, human
  • Tumor Suppressor Protein p53